Ann: Response to ASX aware query, page-4

I like the sound of this....

"On 12th September 2018, Memphasys advised the market that Global IVF Key Opinion Leaders (KOLs) had expressed strong interest to conduct clinical studies on the Felix device and that it was in advanced discussions with several IVF KOLs in the United States, Europe and Australia with a view to having these IVF clinics undertake in-vitro assessments of the Felix device. In the past six months, Memphasys has referred in detail to the planned Felix KOL assessment program in three announcements: 3 May “Felix Device Development Update” (presentation slide 11), 19 July “Pre-eminent IVF clinics to conduct in-vitro studies on Felix”, and 12 September “Felix Development & Commercialisation Update”. – 2 – The MOU signed with ANOVA Karolinska is the first of what is expected to be several MOUs. The MOU is not a formal contract for clinical assessment studies, but rather a non-binding agreement outlining the terms and details of an understanding between the parties and each parties’ requirements and responsibilities, for ANOVA to participate in undertaking studies and to jointly develop the clinical study protocol with Professor John Aitken at University of Newcastle, the key inventor of the technology. Memphasys also notes that interest from KOLs to conduct clinical studies on the FELIX device are ongoing and expects to make announcements in the future as more MOUs are signed and as these clinical studies develop. Memphasys advise that it is not aware of any additional material information that it has not announced to the market, which if known by some in the market, could explain the recent trading in its securities"